Mammoth Biosciences to Develop CRISPR-based Diagnostics, Biosurveillance Platforms
Under the program, Mammoth will leverage its robust DETECTR platform for CRISPR-based diagnostics to detect emerging biological threats.
Read MorePosted by Melanie Hamilton-Basich | Jan 15, 2021 | Company News, Covid 19 |
Under the program, Mammoth will leverage its robust DETECTR platform for CRISPR-based diagnostics to detect emerging biological threats.
Read MorePosted by Laurie Bonner | Jan 15, 2021 | Uncategorized |
A high-throughput test that can predict neutralizing activities is a critical step toward understanding herd immunity to covid-19.
Read MorePosted by Melanie Hamilton-Basich | Jan 13, 2021 | Covid 19 |
The BARDA funding is for the validation and submission of the Simplexa Covid-19 Direct kit and the Simplexa Covid-19 & Flu A/B Direct kit for FDA 510(k) clearance.
Read MorePosted by Melanie Hamilton-Basich | Jan 13, 2021 | Covid 19, Lab Automation |
Aim Lab covid-19 PathFinder benchtop automation solutions can help overcome many covid-19-related challenges.
Read MorePosted by Melanie Hamilton-Basich | Jan 13, 2021 | Covid 19 |
Ortho Clinical Diagnostics’ Vitros SARS-CoV-2 Antigen Test has become the first high-volume covid-19 antigen test to receive FDA emergency use authorization.
Read More